Hemp Therapies Wiki / Liposomal Delivery Systems

Liposomal NAD+

NAD+ (nicotinamide adenine dinucleotide) is a cofactor central to cellular energy metabolism, and liposomal delivery has been marketed as a way around a specific molecular barrier to supplementing it orally.

NAD+‘s Role in Metabolism

NAD+ is an important cofactor in redox reactions and functions as a central regulator of various metabolic processes in the human body. It participates in ATP generation, fatty acid synthesis, cholesterol synthesis, and gluconeogenesis. Most NAD+ in the body is produced through salvage pathways rather than being synthesized from scratch. Sirtuins (SIRT1–7) are a family of NAD+-dependent protein deacetylase enzymes that regulate cellular functions including metabolism and aging-related processes; decreased SIRT6 activity has been associated with abnormal glucose and lipid metabolism in research literature. A meta-analysis covering 40 studies and 14,750 participants examining NAD+ precursor supplementation (nicotinic acid, nicotinamide riboside, nicotinamide) reported statistically significant changes in lipid markers — including lower triglycerides, lower total cholesterol, lower LDL cholesterol, and higher HDL cholesterol — alongside a reported increase in plasma glucose. Effects were concentrated in participants with cardiovascular disease or dyslipidemia, with minimal effect observed in healthy populations, and nicotinic acid specifically showed the strongest lipid effects among the precursors compared.

The Absorption Barrier

The NAD+ molecule is described in research literature as too large and electrically charged to cross cell membranes effectively on its own, cited as a fundamental barrier to direct NAD+ supplementation reaching intracellular targets. As of current published literature, no peer-reviewed human studies have demonstrated that oral liposomal NAD+ supplements increase measurable NAD+ levels in the body — a gap noted directly alongside marketing claims made about the technology. Liposomal delivery has been shown in separate research to improve absorption of some nutrients, such as vitamin C, but equivalent absorption evidence has not been established for NAD+ or its precursor compounds specifically.

Manufacturing Trade-Offs Specific to NAD+

Manufacturing processes used to produce powder or capsule liposomal products can break down the liposome structure itself during processing, described in the literature as rendering the “liposomal” label claim less meaningful for those formats. Liquid liposomal products better preserve the physical liposome structure through manufacturing, but this format has separately been reported to risk degrading the encapsulated active ingredient itself over time; powder formats better preserve the active ingredient but at the cost of destroying the liposome structure — a liquid-vs-powder trade-off specific to this category. Although liposomal technology has an established track record in pharmaceutical manufacturing under strict quality-control standards, dietary supplements marketed as “liposomal” are not necessarily produced to the same rigorous specifications, and may vary in liposome quality or stability between manufacturers. Independent testing referenced in the literature found that a majority of tested top-selling NAD+ supplements — 57% in one report — contained less than 1% of their labeled NAD+-related content, with liposomal-labeled products among the poorer performers in that testing round.

Summary

NAD+ plays a well-established role in cellular metabolism, but the evidence that liposomal delivery specifically overcomes NAD+‘s molecular absorption barrier is currently absent from peer-reviewed human research — a gap the literature notes directly alongside the marketing claims made about liposomal NAD+ products.